Sanofi SA will significantly increase its exposure to the RNAi class of medicines under a plan to take a 12% stake in Alnylam Pharmaceuticals Inc of Cambridge, Massachusetts. The equity deal, valued at $700 million, is linked to rights to Alnylam’s portfolio of rare-disease medicines.
